Biotech Stock Rips Following Key Announcement

Sponsored:

Monday, June 30, 2025

A Nebraska-based biotech company is turning heads so far during Monday’s session after it announced that it is moving forward with manufacturing and process development work in preparation for clinical trails of its KLTO-202, its investigational gen therapy for amyotrophic lateral sclerosis (ALS).

Traders wasted little time buying up shares of Klotho Neurosciences Inc. (Nasdaq:KLTO), pushing the micro cap up to $1.39/share (+93.03%) at the early session high. This move could indicate that the recently momentum of this stock is here to stay following the pop earlier this month. 

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease, multiple sclerosis and rare neurodegenerative diseases. The company's current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject.

Sponsored: